Hematological disorders to benefit from significant level of first-in-class innovation, says GBI Research

摘要

The hematological disorders therapy area, which covers indications such as sickle cell disease, paroxysmal nocturnal hemoglobinuria, anemia, thalassemia and hereditary hemochromatosis, is experiencing a significant level of first-in-class innovation, with 92 of its 327 pipeline programmes with a disclosed molecular target identified as first-in-class, according to business intelligence provider GBI Research.